miRNA in Parkinson's disease:�From pathogenesis to theranostic approaches

dc.contributor.authorElangovan, Ajay
dc.contributor.authorVenkatesan, Dhivya
dc.contributor.authorSelvaraj, Priyanka
dc.contributor.authorPasha, Md. Younus
dc.contributor.authorBabu, Harysh Winster Suresh
dc.contributor.authorIyer, Mahalaxmi
dc.contributor.authorNarayanasamy, Arul
dc.contributor.authorSubramaniam, Mohana Devi
dc.contributor.authorValsala Gopalakrishnan, Abilash
dc.contributor.authorKumar, Nachimuthu Senthil
dc.contributor.authorVellingiri, Balachandar
dc.date.accessioned2024-01-21T10:44:42Z
dc.date.accessioned2024-08-13T13:21:46Z
dc.date.available2024-01-21T10:44:42Z
dc.date.available2024-08-13T13:21:46Z
dc.date.issued2022-12-11T00:00:00
dc.description.abstractParkinson's disease (PD) is an age associated neurological disorder which is specified by cardinal motor symptoms such as tremor, stiffness, bradykinesia, postural instability, and non-motor symptoms. Dopaminergic neurons degradation in substantia nigra region and aggregation of ?Syn are the classic signs of molecular defects noticed in PD pathogenesis. The discovery of microRNAs (miRNA) predicted to have a pivotal part in various processes regarding regularizing the cellular functions. Studies on dysregulation of miRNA in PD pathogenesis has recently gained the concern where our review unravels the role of miRNA expression in PD and its necessity in clinical validation for therapeutic development in PD. Here, we discussed how miRNA associated with ageing process in PD through molecular mechanistic approach of miRNAs on sirtuins, tumor necrosis factor-alpha and interleukin-6, dopamine loss, oxidative stress and autophagic dysregulation. Further we have also conferred the expression of miRNAs affected by SNCA gene expression, neuronal differentiation and its therapeutic potential with PD. In conclusion, we suggest more rigorous studies should be conducted on understanding the mechanisms and functions of miRNA in PD which will eventually lead to discovery of novel and promising therapeutics for PD. � 2022 Wiley Periodicals LLC.en_US
dc.identifier.doi10.1002/jcp.30932
dc.identifier.issn219541
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/3839
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/10.1002/jcp.30932
dc.language.isoen_USen_US
dc.publisherJohn Wiley and Sons Incen_US
dc.subjectageingen_US
dc.subjectdopamineen_US
dc.subjectmicroRNA (miRNA)en_US
dc.subjectParkinson's disease (PD)en_US
dc.subjectpathogenesisen_US
dc.subjecttherapeuticsen_US
dc.titlemiRNA in Parkinson's disease:�From pathogenesis to theranostic approachesen_US
dc.title.journalJournal of Cellular Physiologyen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files